首页> 外文期刊>Drug Design, Development and Therapy >Icariside II ameliorates diabetic nephropathy in streptozotocin-induced diabetic rats
【24h】

Icariside II ameliorates diabetic nephropathy in streptozotocin-induced diabetic rats

机译:伊卡甙II改善链脲佐菌素诱发的糖尿病大鼠的糖尿病肾病

获取原文
       

摘要

Purpose: To investigate the therapeutic effects and potential mechanisms of icariside II (ICA?II) on reversing diabetic nephropathy in streptozotocin (STZ)-induced type I diabetic rats.Methods: Newborn male Sprague Dawley rats were labeled with thymidine analog 5-ethynyl-2-deoxyuridine (EdU) for tracking endogenous label retaining progenitor cells (LRCs). At age of 8?weeks, 48 rats were randomly divided into three groups: normal control group (n=16), diabetes mellitus group (DM; n=16), and diabetes mellitus plus ICA II therapy group (DM+ICA?II, n=16). Eight weeks induced for diabetes with STZ, rats in DM group and DM+ICA II group were treated with vehicle or ICA II (5 mg/kg/day) for another 8 weeks, respectively. Then, blood creatinine, 24-hour urine protein, blood urea nitrogen, and glycosylated hemoglobin were measured, as well as the expression of von Willebrand factor, malondialdehyde, transforming growth factor-β/drosophila mothers against decapentaplegic protein/connective tissue growth factor (TGF-β/Smad/CTGF) signaling, marker of proliferation Ki-67, and EdU+ LRCs in renal tissues.Results: Increased levels of creatinine, 24-hour urine protein, and blood urea nitrogen and remarkably decreased proportion of normal glomeruli and increased proportions of I, IIa, IIb, and III glomeruli were observed in diabetic rats, while ICA II could reverse these changes. Interestingly, ICA II could significantly downregulate the levels of malondialdehyde and TGF-β/Smad/CTGF signaling and increase the expression of von Willebrand factor, Ki-67, and EdU+ LRCs in the kidney.Conclusion: ICA II treatment could ameliorate diabetic nephropathy in STZ-induced diabetic rats by increasing endothelial cell contents, downregulating TGF-β/Smad/CTGF signaling pathway and oxidative stress level, and promoting cell proliferation both in kidney cortex and medulla. These beneficial effects appear to be mediated by its antioxidant capacity and recruitment of endogenous EdU+ progenitor cells into the kidney tissue.
机译:目的:探讨卡那糖苷II(ICA?II)对链脲佐菌素(STZ)诱导的I型糖尿病大鼠糖尿病性肾病逆转的治疗作用及其潜在机制。方法:将新生的雄性Sprague Dawley大鼠用胸苷类似物5-乙炔基-标记。 2-deoxyuridine(EdU)用于追踪内源性标记保留祖细胞(LRC)。在8周龄时,将48只大鼠随机分为三组:正常对照组(n = 16),糖尿病组(DM; n = 16)和糖尿病加ICA II治疗组(DM + ICA?II ,n = 16)。在STZ诱导的糖尿病诱导的8周中,将DM组和DM + ICA II组的大鼠分别用溶媒或ICA II(5 mg / kg /天)治疗另外8周。然后,测量了血肌酐,24小时尿蛋白,血尿素氮和糖基化血红蛋白,以及von Willebrand因子,丙二醛,转化生长因子-β/果蝇母亲对抗去甲肾上腺素能蛋白/结缔组织生长因子的表达( TGF-β/ Smad / CTGF)信号,肾组织中增殖Ki-67和EdU + LRC的标志物。结果:肌酐,24小时尿蛋白和血尿素氮水平升高,正常肾小球比例显着降低并升高在糖尿病大鼠中观察到了I,IIa,IIb和III肾小球的比例,而ICA II可以逆转这些变化。有趣的是,ICA II可以显着下调丙二醛和TGF-β/ Smad / CTGF信号的水平,并增加von Willebrand因子,Ki-67和EdU + LRCs在肾脏中的表达。结论:ICA II治疗可以减轻糖尿病性肾病STZ诱导的糖尿病大鼠通过增加内皮细胞含量,下调TGF-β/ Smad / CTGF信号通路和氧化应激水平并促进肾皮质和髓质中的细胞增殖。这些有益作用似乎是由其抗氧化能力和将内源性EdU +祖细胞募集到肾脏组织中介导的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号